Inotiv Inc
Company Profile
Business description
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Contact
2701 Kent Avenue
West LafayetteIN47906
USAT: +1 765 463-4527
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 September 2026
Employees
2,046
Stocks News & Analysis
stocks
Cheap retail REIT with an attractive yield
stocks
Expanding store network for ASX listed retailer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.30 | 71.80 | 0.79% |
| CAC 40 | 8,446.17 | 62.16 | 0.74% |
| DAX 40 | 25,008.99 | 114.98 | 0.46% |
| Dow JONES (US) | 51,671.03 | 468.77 | 0.92% |
| FTSE 100 | 10,493.14 | 62.52 | 0.60% |
| HKSE | 24,493.95 | 348.72 | -1.40% |
| NASDAQ | 26,683.94 | 795.10 | 3.07% |
| Nikkei 225 | 69,404.50 | 87.00 | 0.13% |
| NZX 50 Index | 13,426.13 | 65.54 | 0.49% |
| S&P 500 | 7,554.29 | 122.83 | 1.65% |
| S&P/ASX 200 | 8,917.70 | 77.30 | 0.87% |
| SSE Composite Index | 4,091.89 | 4.58 | -0.11% |